Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;53(1):15-23.
doi: 10.1007/s15010-024-02393-9. Epub 2024 Sep 26.

A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

Gabriele Maria Leanza #  1 , Emanuele Rando #  1 , Federico Frondizi  2 , Eleonora Taddei  3 , Francesca Giovannenze  3 , Juan P Horcajada  4 , Giancarlo Scoppettuolo  3 , Carlo Torti  1   3
Affiliations

A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

Gabriele Maria Leanza et al. Infection. 2025 Feb.

Abstract

Introduction: Dalbavancin is an antibiotic characterized by an extended half-life and efficacy against methicillin-resistant Staphylococci. Currently, there are only narrative reviews summarizing the evidence about the use of dalbavancin for infective endocarditis (IE), many of which are focused primarily on its use as consolidation therapy. For this reason, we conducted a systematic review to describe the clinical efficacy and the safety of dalbavancin in IE treatment.

Methods: We searched for available evidence using the MEDLINE (PubMed), Embase, Scopus, Cochrane Library and Web of Science libraries, with no restrictions regarding the publication year. The risk of bias was performed using the Cochrane ROBINS-I tool for the comparative studies and the Newcastle-Ottawa Scale for descriptive studies.

Results: Nine studies were included. All of them were observational. Native valve endocarditis was the most common kind of IE found in the studies' populations (128/263, 48.7%), followed by prosthetic valve endocarditis, and cardiovascular implantable electronic device-related endocarditis. Coagulase-negative Staphylococci were the most common pathogens isolated (83/269, 30.1%), followed by S. aureus, Enterococci spp and Streptococci spp. Five out of nine studies documented a clinical failure rate of less than 10%. Dalbavancin showed a favourable safety profile. Dalbavancin appears to be a promising option for the consolidation therapy of IE. However, further studies comparing dalbavancin with standard of care are needed.

Prospero registration number: CRD42023430032.

Keywords: Dalbavancin; Gram-positive; Infective endocarditis; Long acting antibiotics; Sequential therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: JPH has participated in educational programs organized by MSD, Pfizer, Menarini and Angelini, and in advisory boards organized by Advanz Pharma, Tillots, and GILEAD. The other authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
PRISMA flow-chart
See this image and copyright information in PMC

References

    1. Momtazmanesh S, Saeedi Moghaddam S, Malakan Rad E, Azadnajafabad S, Ebrahimi N, Mohammadi E, et al. Global, regional, and national burden and quality of care index of endocarditis: the global burden of disease study 1990–2019. Eur J Prev Cardiol. 2022;29:1287–97. 10.1093/eurjpc/zwab211. - PubMed
    1. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40:3222–32. 10.1093/eurheartj/ehz620. - PubMed
    1. Gatti M, Andreoni M, Pea F, Viale P. Real-world use of Dalbavancin in the era of empowerment of Outpatient Antimicrobial treatment: a careful Appraisal Beyond approved indications focusing on Unmet Clinical needs. Drug Des Devel Ther. 2021;15:3349–78. 10.2147/DDDT.S313756. - PMC - PubMed
    1. Sader HS, Mendes RE, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. J Antimicrob Chemother. 2019;74:1306–10. 10.1093/jac/dkz006. - PubMed
    1. Lefort A, Pavie J, Garry L, Chau F, Fantin B. Activities of Dalbavancin in Vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to Vancomycin and Teicoplanin. Antimicrob Agents Chemother. 2004;48:1061–4. 10.1128/AAC.48.3.1061-1064.2004. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources